Company profile for Orchard Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Orchard Therapeutics is a leading global fully integrated commercial-stage biotech company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies.Orchard has developed a unique expertise in the manufacturing, preclinical and clinical development of gene therapies for rare diseases. The company’s most advanced clinical program, OTL-101 for ADA-SCID (adenosine deaminase severe comb...
Orchard Therapeutics is a leading global fully integrated commercial-stage biotech company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies.Orchard has developed a unique expertise in the manufacturing, preclinical and clinical development of gene therapies for rare diseases. The company’s most advanced clinical program, OTL-101 for ADA-SCID (adenosine deaminase severe combined immunodeficiency), is expected to progress to a BLA (biological license application) with the FDA in 2018.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
United Kingdom
Address
Address
108 Cannon Street London EC4N 6EU
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/10/28/3175097/0/en/Kyowa-Kirin-and-Orchard-Therapeutics-Announce-OTL-200-Granted-Orphan-Regenerative-Medicine-Product-Designation-for-Early-onset-MLD-in-Japan.html

GLOBENEWSWIRE
28 Oct 2025

https://www.globenewswire.com/news-release/2025/07/07/3110914/0/en/Orchard-Therapeutics-Announces-Last-Patient-Treated-in-Registrational-Trial-of-OTL-203-for-MPS-I-Hurler-Syndrome.html

GLOBENEWSWIRE
07 Jul 2025

https://www.globenewswire.com/news-release/2025/05/13/3079960/0/en/Orchard-Therapeutics-Announces-New-England-Journal-of-Medicine-Publication-of-Long-term-Clinical-Outcomes-from-its-HSC-Gene-Therapy-for-MLD-and-Multiple-Presentations-at-ASGCT-2025.html

GLOBENEWSWIRE
13 May 2025

https://www.globenewswire.com/news-release/2025/02/28/3034520/0/en/Orchard-Therapeutics-Announces-Reimbursement-Agreement-in-Spain.html

GLOBENEWSWIRE
28 Feb 2025

https://www.globenewswire.com/news-release/2025/02/12/3024917/0/en/Orchard-Therapeutics-Appoints-Robin-Kenselaar-to-Chief-Commercial-Officer-and-Announces-Multiple-Business-Updates-Pertaining-to-its-Approved-HSC-Gene-Therapy-for-MLD.html

GLOBENEWSWIRE
12 Feb 2025

https://www.globenewswire.com//news-release/2025/02/03/3019546/0/en/Orchard-Therapeutics-Announces-Multiple-Data-Presentations-and-Receives-2025-New-Treatment-Award-at-the-21st-Annual-WORLDSymposium.html

GLOBENEWSWIRE
03 Feb 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty